Dihydro Ergotamine Mesylate
Dihydro Ergotamine Mesylate structure
|
Common Name | Dihydro Ergotamine Mesylate | ||
|---|---|---|---|---|
| CAS Number | 6190-39-2 | Molecular Weight | 679.783 | |
| Density | N/A | Boiling Point | 1001.8ºC at 760 mmHg | |
| Molecular Formula | C34H41N5O8S | Melting Point | 232°C | |
| MSDS | Chinese USA | Flash Point | 559.7ºC | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
Role of 5-HT1B/1Dreceptors in the reduction of formalin-induced nociception and secondary allodynia/hyperalgesia produced by antimigraine drugs in rats
Life Sci. 92(22) , 1046-54, (2013) Aims The present study analyzed the potential antinociceptive effect of the antimigraine drugs sumatriptan, dihydroergotamine or methysergide in rats submitted to the formalin test. Moreover, by using selective antagonists, the role of 5-HT1B/1D serotonergic ... |
|
|
Structural basis for molecular recognition at serotonin receptors.
Science 340(6132) , 610-4, (2013) Serotonin or 5-hydroxytryptamine (5-HT) regulates a wide spectrum of human physiology through the 5-HT receptor family. We report the crystal structures of the human 5-HT1B G protein-coupled receptor bound to the agonist antimigraine medications ergotamine an... |
|
|
Intrapulmonary and intravenous administrations of dihydroergotamine mesylate have similar cardiovascular effects in the conscious dog.
Br. J. Pharmacol. 154(6) , 1254-65, (2008) The effects of intrapulmonary artery (i.p.a.) administration of dihydroergotamine mesylate (DHE) were evaluated.Conscious beagle dogs (n=4) were given DHE via the i.p.a. or i.v. route as two 0.014 mg kg(-1) doses and a 0.14 mg kg(-1) dose given 60 min apart. ... |
|
|
Sensitive and specific liquid chromatographic-tandem mass spectrometric assay for dihydroergotamine and its major metabolite in human plasma.
J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 768(2) , 267-75, (2002) A sensitive and specific procedure for the simultaneous determination of dihydroergotamine (DHE) and its 8'-hydroxylated metabolite (8'-OH-DHE) in human plasma was developed and validated. The analytes were extracted from plasma samples by liquid-liquid extra... |
|
|
MT 300--POZEN: dihydroergotamine mesylate injection.
Drugs R. D. 4(6) , 376-7, (2003) MT 300 is an injectable formulation of dihydroergotamine mesylate (DHE; a serotonin 5-HT1 receptor agonist) that is being developed by POZEN for the acute treatment of migraine. POZEN intends to present MT 300 as a prefilled syringe that can be administered a... |
|
|
Ergotamine tartrate and dihydroergotamine mesylate: safety profiles.
Headache 37 Suppl 1 , S33-41, (1997) Ergotamine tartrate (ET) and dihydroergotamine mesylate (DHE) have been widely and effectively used in the treatment of migraine for many decades, although few randomized, controlled clinical trials have been conducted with these compounds. To compare their s... |
|
|
Combination dihydroergotamine mesylate and heparin sodium with lidocaine HCl. Pharmacokinetics, mechanism of action, clinical efficacy, and adverse effects.
Pharmacotherapy 6(4 Pt 2) , 3S-11S, (1986) Dihydroergotamine(DHE)-heparin combination offers a unique treatment modality for the prevention of deep vein thrombosis. The combination appears to affect all 3 limbs of Virchow's triad: hypercoagulability, venous stasis, and endothelial damage. In most effi... |
|
|
MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine.
Expert Opin. Pharmacother. 13(13) , 1961-8, (2012) Dihydroergotamine mesylate (DHE) has been used as an acute migraine treatment since 1945, although tolerability with intravenous administration has limited its use. MAP0004 is a novel, orally inhaled, aerosol formulation of DHE that provides pulmonary drug de... |
|
|
Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?
Expert Opin. Pharmacother. 11(18) , 3085-93, (2010) Migraine affects approximately 18% of women and 6% of men, and has an immense impact on quality of life and productivity. Advancement in therapeutic options has been slow. For many patients with difficult-to-treat migraine, the appropriate use of dihydroergot... |
|
|
What happens to the old headache medicines?
Headache 52(4) , 701-6, (2012) Old headache medicines never die; they either fade away or come back in disguise. The disguise is often a new route of administration, which may work better, faster, more completely, with fewer adverse events, and/or have certain other advantages. The clinica... |